Antibodies

20 Sep 2018 Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
19 Sep 2018 Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
19 Sep 2018 Agenus Receives Milestone Payment from Incyte
19 Sep 2018 GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier
18 Sep 2018 Sun Pharma Announces Receipt of European Commission Approval For ILUMETRI® (tildrakizumab) By Almirall For Treatment Of Moderate-To-Severe Chronic Plaque Psoriasis
18 Sep 2018 European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
18 Sep 2018 Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
18 Sep 2018 GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer
18 Sep 2018 Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical
17 Sep 2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
17 Sep 2018 Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522
17 Sep 2018 Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
16 Sep 2018 Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults
16 Sep 2018 Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
15 Sep 2018 Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
14 Sep 2018 EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US
14 Sep 2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
14 Sep 2018 FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
14 Sep 2018 US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
13 Sep 2018 New data show LEO Pharma’s Kyntheum® (brodalumab) provides greater probability of achieving complete skin clearance for people with moderate to severe psoriasis compared with ustekinumab
13 Sep 2018 Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
13 Sep 2018 FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
13 Sep 2018 Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer
13 Sep 2018 Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease
13 Sep 2018 FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top